Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Qilian International Holding Group Limited (BGM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: BGM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -66.18% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.48B USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.46 | 52 Weeks Range 3.33 - 17.17 | Updated Date 06/16/2025 |
52 Weeks Range 3.33 - 17.17 | Updated Date 06/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -26.32% | Operating Margin (TTM) -5.41% |
Management Effectiveness
Return on Assets (TTM) -3.84% | Return on Equity (TTM) -16.52% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2465318227 | Price to Sales(TTM) 83.14 |
Enterprise Value 2465318227 | Price to Sales(TTM) 83.14 | ||
Enterprise Value to Revenue 98.23 | Enterprise Value to EBITDA 2801.9 | Shares Outstanding 163960000 | Shares Floating 2832616 |
Shares Outstanding 163960000 | Shares Floating 2832616 | ||
Percent Insiders 7.29 | Percent Institutions - |
Upturn AI SWOT
Qilian International Holding Group Limited
Company Overview
History and Background
Qilian International Holding Group Limited was founded in 2011. It is a China-based pharmaceutical and chemical company focused on the development, manufacture, marketing, and distribution of traditional Chinese medicine products, chemical products, and medical appliances.
Core Business Areas
- Pharmaceutical Products: Development, manufacturing, marketing, and distribution of traditional Chinese medicine products. Includes herbs, extracts, and finished medicines.
- Chemical Products: Manufacturing and sales of chemical products. These products are used in various industrial applications, including pharmaceuticals and manufacturing processes.
- Medical Appliances: Manufacturing and distribution of medical appliances and equipment.
Leadership and Structure
The company's leadership team consists of executives with experience in the pharmaceutical and chemical industries. The organizational structure includes departments for research and development, manufacturing, sales and marketing, and finance.
Top Products and Market Share
Key Offerings
- Traditional Chinese Medicine (TCM) Products: Various TCM products, including herbal medicines and extracts. Market share data is difficult to ascertain precisely due to the fragmented nature of the TCM market in China. Competitors include other TCM manufacturers in China, such as China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
- Chemical Products: Industrial chemicals used in pharmaceutical and other manufacturing processes. Market share is difficult to determine. Competitors: multiple Chinese chemical manufacturers.
- Medical Appliances: A range of medical equipment, however, no information available for Market share is difficult to determine. Competitors: multiple Chinese medical appliance manufacturers.
Market Dynamics
Industry Overview
The pharmaceutical industry in China is experiencing rapid growth, driven by increasing healthcare spending and a growing aging population. The TCM market is also growing, driven by increasing acceptance of traditional medicine.
Positioning
Qilian International is a relatively small player in the Chinese pharmaceutical and chemical industries. Its competitive advantage lies in its focus on TCM products and its manufacturing capabilities.
Total Addressable Market (TAM)
The total addressable market for pharmaceuticals and chemicals in China is substantial, estimated to be hundreds of billions of dollars. Qilian International's positioning allows it to capture a small portion of this market.
Upturn SWOT Analysis
Strengths
- Focus on traditional Chinese medicine
- Manufacturing capabilities
- Established distribution network within China
Weaknesses
- Relatively small market share
- Limited financial resources compared to larger competitors
- Dependence on the Chinese market
Opportunities
- Expanding into new geographic markets
- Developing new TCM products
- Acquiring smaller competitors
Threats
- Increased competition from larger pharmaceutical companies
- Changes in government regulations
- Economic downturn in China
Competitors and Market Share
Key Competitors
- CRHKY
- 000999.SZ
- 600332.SS
Competitive Landscape
Qilian International faces intense competition from larger, more established pharmaceutical and chemical companies in China. Its smaller size and limited resources pose a disadvantage.
Growth Trajectory and Initiatives
Historical Growth: Insufficient data available to assess historical growth trends.
Future Projections: No reliable future projections are available due to limited information and potential delisting issues.
Recent Initiatives: It is difficult to ascertain recent strategic initiatives due to limited reporting.
Summary
Qilian International Holding Group Limited faces substantial challenges. The company's small market share and limited financial resources present significant hurdles in a competitive industry. However, its focus on traditional Chinese medicine provides a potential niche. Availability and reliability of financial data is a major concern, and the company requires strategic initiatives to improve its position and address competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (where available)
- Industry reports
- Financial news sources
- Market research reports
Disclaimers:
The information provided is based on limited publicly available data and may not be entirely accurate or complete. This analysis is for informational purposes only and should not be considered investment advice. The situation surrounding Qilian International Holding Group Limited is dynamic and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Qilian International Holding Group Limited
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2024-08-12 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 298 | Website https://www.bgm.ltd |
Full time employees 298 | Website https://www.bgm.ltd | ||
BGM Group Ltd manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was formerly known as Qilian International Holding Group Limited and changed its name to BGM Group Ltd in October 2024. BGM Group Ltd was incorporated in 2019 and is based in Chengdu, the People's Republic of China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.